| Primary information |
|---|
| ID | antitb_1319, |
| Name | 21464254 |
| N-Terminal modification | 1-C134mer |
| C-Terminal Modification | H-Ntridec-NLys-Nspe-Nspe-NLys-NH2 |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine, Ntridec = N-(tridecyl)glycine |
| Chirality | Linear |
| Nature | 5 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 6.6 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2011 |
| Cytotoxicity | Raw 264.7 and J774 mouse macrophage |
| In vivo Model | NA |
| Lethal Dose | LD50 = >100 μM |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1325, |
| Name | 21464254 |
| N-Terminal modification | 1-C134mer |
| C-Terminal Modification | H-Ntridec-NLys-Nspe-Nspe-NLys-NH2 |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine, Ntridec = N-(tridecyl)glycine |
| Chirality | Linear |
| Nature | 5 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | MIC = 6.3 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2011 |
| Cytotoxicity | Raw 264.7 and J774 mouse macrophage |
| In vivo Model | NA |
| Lethal Dose | LD50 = >100 μM |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |